Rosai-Dorfman病的治疗新进展

doi:10.35541/cjd.20180703

中华皮肤科杂志 ›› 2019, Vol. 52 ›› Issue (10): 785-788.doi: 10.35541/cjd.20180703

• 综述 • 上一篇

Rosai-Dorfman病的治疗新进展

陈秀芳肖嵘湛意张桂英

中南大学湘雅二医院皮肤科，长沙 410011

收稿日期:2018-08-21 修回日期:2018-12-28 发布日期:2019-09-30
通讯作者: 张桂英；湛意 E-mail:lindazgy@csu.edu.cn; misseven69@csu.edu.cn
基金资助:
国家自然科学基金（81502710、81500187）

Treatment of Rosai-Dorfman disease

Chen Xiufang, Xiao Rong, Zhan Yi, Zhang Guiying

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Received:2018-08-21 Revised:2018-12-28 Published:2019-09-30
Contact: Zhang Guiying; Zhan Yi E-mail:lindazgy@csu.edu.cn; misseven69@csu.edu.cn
Supported by:
National Natural Science Foundation of China（81502710, 81500187）

摘要/Abstract

摘要： 【摘要】 Rosai-Dorfman病又称窦性组织细胞增生症伴巨大淋巴结病，是一种临床上罕见的病因不明的良性自限性组织细胞增生症。本病缺乏特异的治疗方法。治疗首选手术，无法进行手术的患者可以选用局部治疗和系统治疗。局部治疗包括外用糖皮质激素或局部封闭治疗，光动力治疗和激光免疫疗法也是很有前景的局部疗法。传统的系统治疗包括糖皮质激素、免疫调节剂、阿维A等；对CD20阳性的Rosai-Dorfman病，利妥昔单抗是一种新的治疗选择。本文就近年来Rosai-Dorfman病的一些治疗新进展予以综述。

关键词: 组织细胞增多症, 窦；治疗；外科手术；药物疗法；窦性组织细胞增生症伴巨大淋巴结病

Abstract: 【Abstract】 Rosai-Dorfman disease （RDD）, also known as sinus histiocytosis with massive lymphadenopathy, is a rare benign self-limited histiocytic proliferative disorder with undetermined etiology. There is still no specific treatment for RDD. Surgical excision is the first-line treatment, while topical and systemic therapy can be chosen for the patients who are not unfit for surgery. Classic topical therapies include topical treatment or local injection with glucocorticoids. Photodynamic therapy and laser immunotherapy are considered as promising topical treatments. Traditional systemic treatments include oral glucocorticoids, immunomodulators, acitretin, and so on. Rituximab is a new treatment option for patients with CD20-positive RDD. This review summarizes new progress in the treatment of RDD in recent years.

Key words: Histiocytosis, sinus, Therapy, Surgical procedures, operative, Drug therapy, Sinus histiocytosis with massive lymphadenopathy

陈秀芳湛意肖嵘张桂英. Rosai-Dorfman病的治疗新进展[J]. 中华皮肤科杂志, 2019,52(10):785-788. doi:10.35541/cjd.20180703

Chen Xiufang, Xiao Rong, Zhan Yi, Zhang Guiying. Treatment of Rosai-Dorfman disease[J]. Chinese Journal of Dermatology, 2019, 52(10): 785-788.doi:10.35541/cjd.20180703

参考文献 26

［1］	Mantilla JG, Goldberg⁃Stein S, Wang Y. Extranodal Rosai⁃Dorfman disease: clinicopathologic series of 10 patients with radiologic correlation and review of the literature［J］. Am J Clin Pathol, 2016,145（2）:211⁃221. doi: 10.1093/ajcp/aqv029.
［2］	张德志, 普雄明, 于世荣, 等. 皮肤病临床表现及组织病理学特征分析［J］. 中华皮肤科杂志, 2018,51（3）:173⁃176. doi: 10.3760/cma.j.issn.0412⁃4030.2018.03.011.
［3］	Al⁃Khateeb TH. Cutaneous Rosai⁃Dorfman disease of the face: a comprehensive literature review and case report［J］. J Oral Maxillofac Surg, 2016,74（3）:528⁃540. doi: 10.1016/j.joms.2015. 09.017.
［4］	Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy （Rosai⁃Dorfman disease）: report of a case and literature review［J］. Am J Hematol, 2002,69（1）:67⁃71. doi: 10.1002/（ISSN）1096⁃8652.
［5］	Forest F, N′guyen AT, Fesselet J, et al. Meningeal Rosai⁃Dorfman disease mimicking meningioma［J］. Ann Hematol, 2014,93（6）:937⁃940. doi: 10.1007/s00277⁃013⁃1994⁃8.
［6］	Satter EK, Graham BS, Steger JW. Response of cutaneous Rosai⁃Dorfman disease to topical and intralesional steroids［J］. Br J Dermatol, 2003,149（3）:672⁃674. doi: 10.1046/j.1365⁃2133.2003. 05499.x.
［7］	罗颖君, 马寒. Rosai⁃Dorfman病发病机制的研究进展［J］. 国际皮肤性病学杂志, 2016,42（4）:247⁃249. doi: 10.3760/cma.j.issn.1673⁃4173.2016.04.014.
［8］	李蕾, 肖玉娟, 阎衡, 等. 伴阳性浆细胞增多的皮肤病一例［J］.中华皮肤科杂志, 2018,51（3）:209⁃211. doi: 10.3760/cma.j.issn. 0412⁃4030.2018.03.011.
［9］	Sun L, Shi J, Su Z, et al. Successful treatment of Rosai⁃Dorfman disease using ALA⁃PDT［J］. Photodiagnosis Photodyn Ther, 2018,21:128⁃129. doi: 10.1016/j.pdpdt.2017.11.014.
［10］	Li M, Shi L, Luo M, et al. Successful treatment of Rosai⁃Dorfman disease using in situ photoimmunotherapy［J］. Indian J Dermatol Venereol Leprol, 2017,83（3）:332⁃336. doi: 10.4103/ijdvl.IJDVL_ 356_16.
［11］	Oka M, Kamo T, Goto N, et al. Successful treatment of Rosai⁃Dorfman disease with low⁃dose oral corticosteroid［J］. J Dermatol, 2009,36（4）:237⁃240. doi: 10.1111/jde.2009.36.issue⁃4.
［12］	鲁丽霞, 粟娟, 施为, 等. 皮肤Rosai⁃Dorfman病1例［J］. 临床皮肤科杂志, 2015,44（2）:106⁃107.
［13］	凌俊, 孙建方, 赵晓广. 糖皮质激素联合羟氯喹治疗皮肤型Rosai⁃Dorfman病1例［J］. 临床皮肤科杂志, 2017,46（4）:276⁃278.doi: 10.16761/j.cnki.1000⁃4963.2017.04.018.
［14］	Chan CC, Chu CY. Dapsone as a potential treatment for cutaneous Rosai⁃Dorfman disease with neutrophilic predominance［J］. Arch Dermatol, 2006,142（4）:428⁃430. doi: 10.1001/archderm.142. 4.428.
［15］	Chang HS, Son SJ, Cho KH, et al. Therapeutic challenge of dapsone in the treatment of purely cutaneous Rosai⁃Dorfman disease［J］. Clin Exp Dermatol, 2011,36（4）:420⁃422. doi: 10. 1111/ced.2011.36.issue⁃4.
［16］	Tjiu JW, Hsiao CH, Tsai TF. Cutaneous Rosai⁃Dorfman disease: remission with thalidomide treatment［J］. Br J Dermatol, 2003,148（5）:1060⁃1061. doi: 10.1046/j.1365⁃2133.2003.05311.x.
［17］	Chen E, Pavlidakey P, Sami N. Rosai⁃Dorfman disease successfully treated with thalidomide［J］. JAAD Case Rep, 2016,2（5）:369⁃372. doi: 10.1016/j.jdcr.2016.08.006.
［18］	Rubinstein M, Assal A, Scherba M, et al. Lenalidomide in the treatment of Rosai Dorfman disease⁃a first in use report［J］. Am J Hematol, 2016,91（2）:E1. doi: 10.1002/ajh.24225.
［19］	Anderson KC. Lenalidomide and thalidomide: mechanisms of action⁃⁃similarities and differences［J］. Semin Hematol, 2005,42（4 Suppl 4）:S3⁃S8. doi: 10.1053/j.seminhematol.2005.10.001.
［20］	Mebazaa A, Trabelsi S, Denguezli M, et al. Extensive purely cutaneous Rosai⁃Dorfman disease responsive to acitretin［J］. Int J Dermatol, 2007,46（11）:1208⁃1210. doi: 10.1111/ijd.2007.46.issue⁃11.
［21］	Chang LY, Kuo TT, Chan HL. Extranodal Rosai⁃Dorfman disease with cutaneous, ophthalmic and laryngeal involvement: report of a case treated with isotretinoin［J］.Int J Dermatol, 2002,41（12）:888⁃891. doi: 10.1046/j.1365⁃4362.2002.01675.x.
［22］	赵辨. 中国临床皮肤病学［M］. 2版. 南京: 江苏科学技术出版社, 2017:314.
［23］	Nadal M, Kervarrec T, Machet MC, et al. Cutaneous Rosai⁃Dorfman disease located on the breast: rapid effectiveness of methotrexate after failure of topical corticosteroids, acitretin and thalidomide［J］. Acta Derm Venereol, 2015,95（6）:758⁃759. doi: 10.2340/00015555⁃2057.
［24］	王小坡, 孙建方. 甲氨蝶呤口服联合复方倍他米松注射液皮损内注射治疗皮肤Rosai⁃Dorfman病一例［J］. 中华皮肤科杂志, 2016,49（9）:662. doi: 10.3760/cma.j.issn.0412⁃4030.2016.09. 016.
［25］	Liu P, Wang P, Du J, et al. Successful treatment of refractory cutaneous Rosai⁃Dorfman disease with vincristine［J］. J Dermatol, 2015,42（1）:97⁃98. doi: 10.1111/1346⁃8138.12694.
［26］	Averitt AW, Heym K, Akers L, et al. Sinus histiocytosis with massive lymphadenopathy （Rosai Dorfman disease）: diagnostic and treatment modalitiesfor this rare entity revisited［J］. J Pediatr Hematol Oncol, 2018,40（4）:e198⁃e202. doi: 10.1097/MPH.0000000000001044.

[1]	关军帅华洲王兰兰王春艳程平胡彬易雪邹亮程辉. 皮肤T细胞淋巴瘤继发噬血细胞性淋巴组织细胞增多症7例临床分析[J]. 中华皮肤科杂志, 2023, 56(2): 105-111.
[2]	张莹陈浩孙建方. 皮肤Rosai-Dorfman病的研究进展[J]. 中华皮肤科杂志, 2019, 52(2): 138-141.
[3]	李蕾肖玉娟阎横郝进刁庆春. 伴IgG4阳性浆细胞增多的皮肤Rosai-Dorfman病一例[J]. 中华皮肤科杂志, 2018, 51(3): 209-211.
[4]	张德志普雄明于世荣丁媛康晓静. 皮肤Rosai-Dorfman病临床表现及组织病理学特征分析[J]. 中华皮肤科杂志, 2018, 51(3): 173-176.
[5]	徐教生刘元香徐哲张立新徐子刚高子芬马琳. 儿童原发性皮肤γδ-T细胞淋巴瘤合并噬血细胞综合征一例[J]. 中华皮肤科杂志, 2013, 46(12): 851-854.
[6]	殷发任俊杰任雯. 多中心网状组织细胞增生症一例[J]. 中华皮肤科杂志, 2009, 42(9): 599-599.
[7]	林尽染, 陈明华, 陈波斌, 黄琼, 徐金华. 朗格汉斯细胞组织细胞增多症伴干燥综合征一例[J]. 中华皮肤科杂志, 2008, 41(12): 800-802.
[8]	符美华, 顾黎雄, 陈伟, 陈辉, 李和莲, 刘维达, 孙建方. 老年慢性多灶性朗格汉斯细胞增生症一例[J]. 中华皮肤科杂志, 2007, 40(10): 601-603.
[9]	王健美, 唐曙, 陈仁贵, 凌波. Langerhans细胞组织细胞增生症的免疫组化电镜及DNA流式细胞计数研究[J]. 中华皮肤科杂志, 1995, 28(4): 222-225.

Rosai-Dorfman病的治疗新进展

Treatment of Rosai-Dorfman disease

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 9

Metrics

本文评价

推荐阅读 10